Navigation Links
Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data

to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; unexpected clinical trial results, including additional analysis of clinical data, or new clinical data; unexpected regulatory actions or delays or government regulation generally; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

Post Your Comments:
(Date:11/5/2009)...OVATO, Calif., Nov. 5 Bi...ced today that the United States Patent and Tradem...ed administration of Kuvan® (sapropterin dihy...ketonuria (PKU). The patent expires in 2024. ,...n the discovery that food increases the bioavailab...
(Date:11/5/2009)...MERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -... and development company focused on the unmet need...third quarter highlights and financial results for...Subsequent to the end of the quarter, in October 2...ing and issued approximately 31 million shares of ...
(Date:11/5/2009)...AN DIEGO, Nov. 5 CareFus... device company created on Sept. 1 through the spi...ducts businesses, today reported increases in reve...t quarter of its fiscal 2010 and raised its full-y...h our strong results during the first quarter whil...
Breaking Medicine Technology:United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 3United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9CareFusion Reports First Quarter Results, Raises Full-Year Outlook 2CareFusion Reports First Quarter Results, Raises Full-Year Outlook 3CareFusion Reports First Quarter Results, Raises Full-Year Outlook 4CareFusion Reports First Quarter Results, Raises Full-Year Outlook 5CareFusion Reports First Quarter Results, Raises Full-Year Outlook 6CareFusion Reports First Quarter Results, Raises Full-Year Outlook 7CareFusion Reports First Quarter Results, Raises Full-Year Outlook 8CareFusion Reports First Quarter Results, Raises Full-Year Outlook 9CareFusion Reports First Quarter Results, Raises Full-Year Outlook 10CareFusion Reports First Quarter Results, Raises Full-Year Outlook 11CareFusion Reports First Quarter Results, Raises Full-Year Outlook 12American Association for Homecare Supports Crackdown on Medicare Scammers in Houston Boston New York Louisiana 53300 1American Association for Homecare Supports Crackdown on Medicare Scammers in Houston Boston New York Louisiana 53300 2American Association for Homecare Supports Crackdown on Medicare Scammers in Houston Boston New York Louisiana 53300 3American Association for Homecare Supports Crackdown on Medicare Scammers in Houston Boston New York Louisiana 53300 4TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 13301 1TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 13301 2TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 13301 3TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction 13301 4PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 1PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 2PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 3PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 4PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 5PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 6PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 7PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 8PDL BioPharma Announces Second Quarter 2009 Financial Results 53293 9
...HOLX ), a leading developer, manufacturer and supp...ms and surgical products dedicated to,serving the ...ults of the,Cervista HPV high-risk pivotal clinica...tly under review by the FDA in the U.S. and is exp...rly in 2009. The clinical and,analytical performan...
...geons,at the University of Rochester Medical Cente... be converted to an endovascular simulator,(ANGIO ... The surgeons,"strongly agreed" that the simulatio...fety and efficiency of instrument use, decreased,o...nt of contrast used, and,that the operative and si...
Other Medicine Technology:Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2
(Date:11/5/2009)...v. 5 Allied World Assura...rted net income of $200.6 million,or $3.83 per di...d to a net,loss of $46.4 million, or $0.95 per dil...come for the nine months ended September 30, 2009 ...mpared to net income of,$163.8 million, or $3.22 d...
(Date:11/5/2009)...stein, MBBCh, Executive Vice President of the Uni... Dean, School of Medicine, will receive the Abraha...al Education from the Association of American Medi...n Saturday, Nov. 7, during the association,s annua...stablished by the AAMC in 1958 to recognize extrao...
(Date:11/5/2009)..., a world leader in online-based medical transcrip...tive immediately. , (Vocu...online-based medical transcription, has tapped Ran... , , ,Emdat’s founding partners, who remain... to serve as CEO of the 10-year-old company. Steve...
(Date:11/5/2009)...g of human diseases, scientists say , , ... the domestic horse has been sequenced, an accompl...nd may help studies of human health, according to ... access to multiple genome sequences makes it easi...y looking at the horse genome, we can better under...
(Date:11/5/2009)... One jerk in a bar spends the night delivering bad...e women aren,t receptive to even the nicest guys a...onary theory. Males increase their fitness by acqu...ase for females and therein lies the conflict. ,...versity of Arizona studied sexual conflict in wate...
Breaking Medicine News(10 mins):Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 2Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 3Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 4Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 5Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 6Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 7Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 8Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 9Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 10Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 11Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 12Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 13Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 14Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 15Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 16Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 17Health News:Allied World Reports Record Operating Results in Third Quarter 2009; 27.4% Increase in Total Book Value Year to Date; 11% Dividend Increase Announced 18Health News:Penn's Arthur H. Rubenstein receives Distinguished Service award from AAMC 2Health News:Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider 2Health News:Complete Horse Genome Sequence Revealed 2Health News:Mom was right: Nice guys don't always finish last 2
...ct. 20 Four years after their 12-year-old,daughte...r for a secret,abortion to cover up his crime, a S...d and reported it to police. Without the parents, ...ia had a law requiring abortion providers to infor...
...t. 20 Bronstein, Gewirtz & Grossman, LLC,announce...e United States,District Court for the District of..."Spectranetics" or the "Company") (Nasdaq: SPNC )...Period")., According to the complaint, the true f...
... Silicon Merges High-Performance Data Conversion W...pression, SANTA CLARA, Calif., Oct. 20 Samplify ... solutions, today announces its move,from intellec...: Samplify Announces SAM1600 Family) Samplify maxi...
... New plan incorporates new managemen...ce companies. , Alpharett...that healthcare in this country is in crisis, that... to lowering malpractice rates. But according to R...
... Twenty-five years of work culminate...ist claims Pearlinbrite is more effective and prec...earlinbrite is more effective and precise than oth... unique in-office laser whitening system. Pearlin...
...Annual Physicians, Office Pulse Report Released To... Associates,Inc. report released today confirms pa...h care experience and feel more empowered to choos...tention,rates. The 2008 Physicians, Office Pulse R...
Other Medicine News:Health News:Why Law Enforcement Supports Proposition 4 2Health News:Bronstein, Gewirtz & Grossman, LLC Announces that a Class Action has been Filed Against The Spectranetics Corporation 2Health News:Samplify Evolves Business Model From IP Developer to Semiconductor Supplier; Now Targets Multi-Billion Dollar Market 2Health News:CEO Proposes a Radical Plan to Revamp the Healthcare System 2Health News:CEO Proposes a Radical Plan to Revamp the Healthcare System 3Health News:Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 2Health News:Report Confirms Consumer Selection is a Driving Force in Health Care Today 3
Miller Collburn Periosteal Elevators
Williger Periosteal Elevators
Farabeuf Periosteal Elevators
Cottle Periosteal & Skin Elevator
Medicine Products: